ERX1000 - A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity
Latest Information Update: 27 Oct 2023
At a glance
- Drugs ERX 1000 (Primary) ; Calcium carbonate/magnesium hydroxide
- Indications Obesity
- Focus Adverse reactions
- Sponsors ERX Pharmaceuticals
- 23 Oct 2023 Status changed from recruiting to completed.
- 11 May 2023 Planned End Date changed from 3 Jun 2023 to 3 Jul 2023.
- 11 May 2023 Planned primary completion date changed from 3 Jun 2023 to 3 Jul 2023.